Case report of three patients with end-stage recurrent glioblastoma treated with meldonium
https://pubmed.ncbi.nlm.nih.gov/40295665/
Results: Meldonium was well tolerated by all three patients. One patient experienced long-term growth arrest and maintained clinically stable disease status, currently 24 months into treatment with meldonium. In contrast, the other two patients passed away.